Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vatreptacog alfa for acute bleeding episodes in congenital haemophilia with inhibitors
2010-023803-92Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of vatreptacog alfa in hemophilia A and hemophilia B (HB), sponsored by Novo Nordisk. Primary endpoint: Effective bleeding control. Started May 2011; status: completed.
02
Drugs
vatreptacog alfa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on 2010-023803-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023803-92.